pills-tablets.jpgIPNews® – GlaxoSmithKline LLC and Teva Pharmaceutical Industries Ltd. were accused in a new class action in New Jersey federal court on Thursday of striking illegal deals to delay the entry of generic versions of Glaxo’s epilepsy drug Lamictal to the market until Glaxo’s patent for it expired.

Glaxo sued Teva after it filed an abbreviated new drug application for generic Lamictal. After a judge invalidated a key Lamictal patent claim, the companies agreed to settle to preserve the patent’s validity and Teva’s 180-day exclusivity period, The International Brotherhood of Electrical Workers Local 595 Health and Welfare Fund says. To continue reading, click: Union Sues Glaxo, Teva Over Lamictal Pay-For-Delay Patent Deal